Farmas USA

Para de aquí a un par de décadas: gotas para las cataratas

Cataracts Melt Away Thanks To New Eye Drops Containing Steroid Lanosterol

http://www.medicaldaily.com/cataracts-melt-away-thanks-new-eye-drops-containing-steroid-lanosterol-344450

https://www.fightaging.org/archives/2015/07/lanosterol-versus-cataracts-promising-initial-results.php

Though scientists don't fully understand how cataracts form, they do know that the "fog" often seen by patients is a glob of broken proteins, stuck together in a malfunctioning clump. When healthy, these proteins, called crystallins, help the eye's lens keep its structure and transparency. But as humans and animals alike get older, these crystallin proteins start to come unglued and lose their ability to function. Then they clump together and form a sheathlike obstruction in the lens, causing the signature "steamy glass" vision that accompanies cataracts. Researchers came up with the eye drop idea after finding that children with a genetically inherited form of cataracts shared a mutation that stopped the production of lanosterol, an important steroid in the body. When their parents did not have the same mutation, the adults produced lanosterol and had no cataracts.

So the researchers wondered: What if lanosterol helped prevent or reduce cataracts? The team tested a lanosterol-laden solution in three separate experiments. First, they used human lens cells to test how effectively lanosterol shrank lab models of cataracts. They saw a significant decrease. Then, they progressed to rabbits suffering from cataracts. At the end of the 6-day experiment, 11 of 13 rabbits had gone from having severe or significant cataracts to mild cataracts or no cataracts at all. Finally, the team moved on to dogs with naturally occurring cataracts. The dogs responded just as the researchers hoped to the lanosterol solution, which was given in the form of both eye injections and eye drops. The dogs' lenses showed the same type of dissolving pattern as the human and rabbit lens cells. The improvement was remarkable - researchers could tell just by looking at the dogs' eyes that the cataracts had decreased. But the exact mechanism of how lanosterol manages to disperse the mass of proteins remains unknown.

GALE

Acababa de borrar la noticia por duplicada, pero prefiero dejarla para los que no entiendan ese español ininteligible traducido de Google. Cuando lo uséis, por favor, poned también el enlace del original al menos.

Galena Biopharma (NASDAQ: GALE) announced the product launch for Zuplenz (ondansetron) Oral Soluble Film in the United States.

Zuplenz is now available nationwide and is supplied in both 4 mg and 8 mg strengths. Zuplenz is clinically bioequivalent to ondansetron orally disintegrating tablets (ODT) with a safety profile equivalent to ondansetron. The novel, PharmFilm® oral soluble film technology utilized by Zuplenz provides for convenient delivery and several key patient benefits including:

Rapidly dissolves in the mouth in about 10 seconds
Eliminates the burden of swallowing pills during emesis and in cases of oral irritation
Does not require water to administer
Pleasant peppermint flavor with no gritty aftertaste
Non-sedating

"Ondansetron is the gold-standard treatment option for patients suffering from nausea and vomiting due to chemotherapy, radiation treatments, and surgical procedures; and, we believe the unique and innovative product attributes of Zuplenz will be a valuable treatment option for patients and physicians to relieve these debilitating side-effects," said Mark W. Schwartz, Ph.D., President and Chief Executive Officer. "With the launch of Zuplenz, we will leverage our existing commercial infrastructure including our outsourced Galena Patient Services (GPS) program to work directly with the patient, prescriber, insurance provider, and pharmacy to help guide the process of getting the patient their medication once prescribed by the physician."

Zuplenz is approved in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV). Zuplenz is also approved for moderately emetogenic CINV in pediatric patients four years and older.

The active pharmaceutical ingredient in Zuplenz, ondansetron, is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. The National Comprehensive Cancer Network (NCCN) 2014 guidelines recommend the use of ondansetron in patients with highly and moderately emetogenic cancer chemotherapy-induced and radiotherapy-induced nausea and vomiting. Ondansetron belongs to a class of medications called serotonin 5-HT3 receptor antagonists and works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. According to data from both IMS and Wolters Kluwer, the branded 5-HT3 market exceeded $1 billion in the U.S. in 2014. The product was licensed from MonoSol Rx, LLC, the developer of the oral soluble film technology, PharmFilm®, and manufacturer of the product.

Estos de Galena vendiendo son peores que los de Amarin, Abstral un desastre, esperando los earnings estoy, y el ondasetron a ver si venden algo, dentro de 6 meses lo sabremos.

GALE

Me dan mas juego las medianas que puse el otro día. ;-)))))

Edito: Me alegra ver que no soy el único que hace este tipo de "pruebas".

Empresones, incluido Biogen, le sumaría Regeneron.

A ver si es verdad... tengo varios familiares, padre y abuelo incluidos, a los que han tenido que intervenir de cataratas, así que soy gran candidato a pasar por el quirófano si no encuentran una solución menos intrusiva en las próximas 2-3 décadas.

TIG

Como la sigo de reojo y me parece que alguien se ha sumado, os pego la propuesta de la junta extraordinaria prevista para el 12 de agosto de ampliación de capital. La noticia es de hace días: 10 de julio.

The shareholders' meeting resolves to authorise the board of directors to increase the Company's registered capital in one or more transactions by a (cumulated) amount equal to the current amount of the registered capital of the Company, i.e. sixteen million forty-seven thousand six hundred sixty-two euro (EUR 16,047,662.00).

TIG

Yo la voy siguiendo, la tengo en mi lista de seguimientos...